Vaxcyte, Inc.
PCVXNASDAQHealthcare● Active
$46.21
$-1.15(-2.43%)
Market Cap$6.7B
P/E Ratio—
52W High$65
52W Low$29.08
Vaxcyte, Inc.（PCVX）· 损益表
年度 / 季度 / TTM 视图 · SEC 10-K 与 10-Q（经 FMP 聚合）· 可在下方切换周期与 M/B/T 单位。
FMP · PCVX · 截至 2026-06-08
财务报表
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Cost of Revenue | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Gross Profit | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Gross Margin %(computed) | — | — | — | — | — |
| Operating Expenses | |||||
| R&D Expenses | $0.79B | $0.48B | $0.33B | $0.17B | $0.08B |
| G&A Expenses | $0.13B | $0.09B | $0.06B | $0.04B | $0.03B |
| Total Operating Expenses | $0.92B | $0.57B | $0.47B | $0.23B | $0.10B |
| Operating Income | ($0.92B) | ($0.57B) | ($0.47B) | ($0.23B) | ($0.10B) |
| Operating Margin %(computed) | — | — | — | — | — |
| Interest Income | $0.12B | $0.11B | $0.06B | $0.01B | $0.00B |
| Interest Expense | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Income Before Tax | ($0.77B) | ($0.46B) | ($0.40B) | ($0.22B) | ($0.10B) |
| Income Tax Expense | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Net Income | ($0.77B) | ($0.46B) | ($0.40B) | ($0.22B) | ($0.10B) |
| Net Margin %(computed) | — | — | — | — | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-5.63 | $-3.80 | $-4.14 | $-3.44 | $-1.93 |
| Wtd Avg Shares | 0.14B | 0.12B | 0.10B | 0.06B | 0.05B |
| EBITDA | ($0.74B) | ($0.45B) | ($0.39B) | ($0.21B) | ($0.10B) |
| EBITDA Margin %(computed) | — | — | — | — | — |
数据来源：Financial Modeling Prep · 最后更新：2026-06-08 · USD · B
深入了解Vaxcyte, Inc.
关于Vaxcyte, Inc.（PCVX）损益表
Vaxcyte, Inc.（PCVX）损益表数据来源于SEC Form 10-K及10-Q申报文件。2025财年，PCVX实现营收$0.00B，毛利润$0.00B（毛利率—），净利润($0.77B)（净利率—）。
常见问题
PCVX · 4 问Vaxcyte, Inc.（PCVX）2025财年营收为$0.00B，同比down—%。
PCVX revenuePCVX salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08